CNC

Business profile & competitive position

Centene Corp. (CNC) sits in the Healthcare sector, specifically the Medical - Healthcare Plans industry. The company is the largest Medicaid insurer, the largest Marketplace insurer, and the largest stand-alone Prescription Drug Plan (PDP) provider in the United States. Its membership stood at 27.6 million as of December 31, 2025, split among 12.5 million Medicaid, 5.5 million Marketplace, and 8.1 million stand-alone PDP members. Its revenue mix is similarly government-program heavy: for 2025, 57% of revenue came from Medicaid, 21% from Commercial, 19% from Medicare, and 3% from Other; total revenue was $194.8 billion and operating cash flow was $5.1 billion.

That scale gives Centene enormous reach, but the current margin figures tell a more complicated story. The company posted a net margin of -2.6% and ROE of -24.0%, and the P/E ratio is -6.1x. Those numbers do not indicate a comfortably profitable moat; they indicate that Centene is generating losses despite its membership scale. Competitive position here is better understood as scale leadership in heavily regulated, low-margin government-sponsored markets rather than as a wide, cash-generating franchise. The sheer enrollment base may create cost and network advantages, yet the negative returns show those advantages are not translating into bottom-line profits right now.

Financial posture

Centene currently commands a market capitalization of $31.1 billion, with the stock changing hands near $62.99. A negative P/E of -6.1 and negative margins mean the company has no positive trailing earnings to compress or expand; the stock is being valued against assets, cash flow, and recovery expectations rather than traditional earnings multiples.

The ROE of -24.0% means every dollar of book equity is currently producing a loss, and the net margin of -2.6% shows operating leverage is working against the company at the current revenue level. CFO of $5.1 billion on $194.8 billion in revenue still leaves meaningful cash generation capacity, but the gap between operating cash flow and reported net income points to non-cash items like goodwill impairments, reserve changes, or acquisition-related accounting that are weighing on headline earnings. The beta of 1.11 suggests the stock moves slightly more than the broader market, consistent with a regulated payer whose earnings are sensitive to policy headlines and medical-cost trends.

Strategic priorities & outlook

Centene’s most recent 10-K lays out a clear set of management priorities, all anchored in repositioning rather than expanding everywhere at once.

• Medicare footprint rationalization: The company is refining its Medicare operations to overlap more closely with its Medicaid footprint and is expanding Dual-Eligible Special Needs Plans (D-SNP), which combine Medicare and Medicaid benefits.
• D-SNP enterprise focus through 2030: Centene is treating the D-SNP opportunity as a long-term growth driver, aligning integrated products with CMS requirements that take effect through 2030.
• Policy advocacy: Management says it plans to advocate for policies and legislation that preserve affordable Medicaid and Marketplace coverage, plus cost-effective PDP benefits.
• Corrective Marketplace pricing and Ambetter expansion: For 2026, Centene plans corrective Marketplace pricing actions in states covering 95% of Marketplace membership and intends to expand Ambetter Health Solutions / ICHRA-compatible off-exchange coverage from 6 states to 13 states.
• Magellan divestiture: In December 2025 the company signed a definitive agreement to divest the remaining Magellan Health businesses, further narrowing the portfolio around core managed care.

The takeaway is operational discipline: withdraw from poorly performing geographies, fix Marketplace pricing, lean into integrated D-SNP products, and exit non-core assets.

Macro & geopolitical exposure

As a managed-care company operating primarily in Medicaid, Medicare, and the ACA Marketplace, Centene is exposed to a policy-heavy macro environment rather than purely economic GDP cycles. Key industry-level exposures include:

• Federal and state Medicaid funding: Medicaid is jointly financed by Washington and state capitals, so changes to Federal Medical Assistance Percentage (FMAP) formulas, work requirements, or eligibility rules flow directly into enrollment and reimbursement.
• CMS regulation: Medicare Advantage and PDP benchmarks, star ratings, prior-authorization rules, and risk-adjustment audits set by the Centers for Medicare & Medicaid Services directly affect revenue and margin.
• Marketplace subsidies and policy: Enhanced ACA subsidies can expand enrollment; their removal or contraction can shrink it. Litigation and executive-branch rulemaking around the Affordable Care Act remain recurring risks.
• Medical-cost inflation and pharmacy costs: Drug pricing, hospital consolidation, and utilization spikes affect medical loss ratios industrywide.
• Interest rates: Managed care companies maintain large investment portfolios of fixed-income securities, so rising or falling rates affect reinvestment yields and unrealized gains/losses.

These factors are inherent to the Medical - Healthcare Plans industry and are especially pronounced for a company whose business is majority government-sponsored.

Recent developments

A short cluster of recent headlines shows Centene is popping up on value and growth screens while it prepares for the 2027 Medicare selling season.

• On October 1, 2026, Zacks listed Centene among its “Best Growth Stocks to Buy for October 1st” (zacks.com).
• Also on October 1, 2026, a PR Newswire headline announced “Wellcare Unveils 2027 Medicare Offerings Focused on Affordability and Integrated Care.” Wellcare is Centene’s Medicare brand, and the 2027 plan rollout lines up with management’s strategy to refine Medicare offerings and push integrated care.
• On September 30, 2026, Zacks featured Centene in “5 Low P/B Stocks With Attractive Value and Strong Growth Potential” (zacks.com).
• On September 29, 2026, Zacks again named it among “Best Growth Stocks to Buy for September 29th” (zacks.com).

These are not company-specific news events, but the repeated inclusion in value and growth screens indicates that algorithmic and quantitative investors are seeing a combination of beaten-down valuation metrics and underlying operating momentum. The Wellcare 2027 announcement is the most fundamentally relevant item, since it ties directly to the D-SNP and integrated-care priorities laid out in the 10-K.

Earnings behavior & post-earnings drift

Centene has an unusually strong recent earnings record but a volatile one-day reaction pattern.

• Over the last 8 reported quarters, the company has beaten estimates 7 times, for a beat rate of 88%.
• The average earnings surprise over that span is 63.1%, an exceptionally high figure driven partly by depressed estimates and one very large outlier.
• The average 5-day post-earnings move across those quarters is +2.83%, classified as an “up” drift.

The last four reports illustrate the contrast between headline beats and immediate price action:

• July 28, 2026: EPS of $2.51 versus the estimate of $1.09, a 130.3% surprise. The stock fell -3.27% the next day but drifted only +0.25% over the next five sessions.
• April 28, 2026: EPS of $3.37 versus the estimate of $2.23, a 51.1% surprise. The stock jumped +8.9% the next day and +6.88% over the following five sessions.
• February 6, 2026: EPS of -$1.19 versus the estimate of -$1.22007, a 2.5% surprise. The stock fell -1.09% the next day but then drifted up +5.51% over the next five sessions.
• October 29, 2025: EPS of $0.50 versus the estimate of -$0.14475, a 445.4% surprise. The stock dropped -6.21% the next day and -1.34% over the following five sessions.

The next scheduled report is October 27, 2026, before the open, with the current consensus EPS estimate at just $0.09574. That estimate is far below the most recent quarterly results, suggesting analysts have baked in significant headwinds or conservatism going into the print. Historically, Centene has cleared estimates by wide margins, but the next-day price reaction has not always rewarded that beat.

For a deeper look at how sell-side and institutional models view Centene’s D-SNP opportunity, Medicare repricing, and path back to positive earnings, pull up the full institutional verdict and compare the underlying consensus assumptions with the numbers above.